---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-26-000128"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2026-10-15T12:46:40+00:00"
generated_at: "2026-10-15T12:50:23.266617+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Recursion prices $200M equity offering, reports Sanofi option milestone and early clinical data

## Summary
- Recursion priced 61,540,000 Class A shares at $3.25/share for ~$200M gross proceeds; offering expected to close Oct 16, 2026.
- Preliminary Sept 30, 2026 cash, equivalents and restricted cash ~$561M, including ~$86M net ATM proceeds from 23,696,330 shares; runway into 2029.
- Sanofi optioned first collaboration development candidate; triggered $10M milestone, bringing total payments to $144M; Recursion eligible for >$300M more and low double-digit royalties.
- REC-4881 TUPELO Phase 1b/2: 87% of 16 efficacy-evaluable FAP patients had polyp burden reductions, 47% median reduction at week 13; no Grade 4/5 TRAEs.
- REC-1245 DAHLIA Phase 1: 91.7% (11/12) at 45/65 mg achieved disease control at 8 weeks; 45 mg selected for expansion after 65 mg exceeded MTD.

## SEC filing metadata
- accession: 0001601830-26-000128
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2026-10-15T12:46:40+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/0001601830-26-000128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/rxrx-20261015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-26-000128
- JSON: https://secwatch.observer/filing/0001601830-26-000128.json
- Plain text: https://secwatch.observer/filing/0001601830-26-000128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.